Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ampio Pharmaceuticals, Inc. Investors

September 17, 2018

BENSALEM, Pa.--(BUSINESS WIRE)--Sep 17, 2018--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE ) securities between  December 14, 2017 and August 7, 2018, inclusive (the “Class Period”). Ampio investors have until  October 24, 2018,  to file a lead plaintiff motion.

Investors that suffered losses on their Ampio investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On August 7, 2018, Ampio disclosed that the U.S. Food and Drug Administration (“FDA”) notified the Company that the FDA does not consider the Company’s AP-003-C trial to be an adequate and well-controlled clinical trial, and that the Company’s AP-003-A study, alone, does not appear to provide sufficient evidence of effectiveness to support a biologics license application.

On this news, Ampio’s share price fell $2.25, or more than 78%, to close at $0.61 per share on August 8, 2018, thereby injuring investors.

The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

If you purchased shares of Ampio during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005763/en/

CONTACT: Law Offices of Howard G. Smith

Howard G. Smith, Esquire







SOURCE: Law Offices of Howard G. Smith

Copyright Business Wire 2018.

PUB: 09/17/2018 04:35 PM/DISC: 09/17/2018 04:35 PM


Update hourly